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1. Introduction
Parkinson’s disease (PD) is a progressive, disabling neurodegene­
rative movement disorder. Medical treatments that treat many of the 
motor symptoms of the disease are available.[1] Unfortunately, after 
prolonged exposure to oral levodopa, motor complications may arise 
with patients rapidly changing from periods of limited movement 
(akinesia/‘off ’) to periods of excessive movements that may range 
from mild to severe and disabling (dyskinesias). Although there 
are several medication­based strategies to reduce these levodopa­
induced motor complications, ultimately the majority of these fail or 
become excessively burdensome to the patient.[2]
The history of deep brain stimulation (DBS) began in the 1940s, 
when because there was limited medication available for the treatment 
of PD, emphasis came to be placed on the use of surgically induced 
lesions of the thalamus and internal segment of the globus pallidus 
(GPi). With the advent and widespread use of dopamine in the 1960s, 
surgery fell out of favour until the reintroduction of pallidotomy 
by Laitinen.[3] It was subsequently shown that high­frequency DBS 
was able to simulate the effects of ablation surgery of basal ganglia 
targets in a reversible and adjustable manner. With the renaissance 
of functional neurosurgery in this field, DBS is now considered an 
important treatment for PD, dystonia and tremor. DBS has been used 
for the treatment of movement disorders in South Africa (SA) since 
Dr Roger Melvill did the first procedure in 2000, and DBS procedures 
have been performed at a wide range of hospitals in both the private 
and the state sectors.
2. Stakeholder involvement
DBS guidelines were discussed at a meeting held on 4 July 2013 in 
Johannesburg, SA. At the time of writing, DBS has been provided at 
five academic centres in the state sector: Inkosi Albert Luthuli Central 
Hospital (KwaZulu­Natal), Universitas Hospital (Free State) and Red 
Cross Children’s, Groote Schuur and Tygerberg hospitals (Western 
Cape), although financial constraints for obtaining DBS equipment 
are significant in the state sector. DBS has also been carried out at a 
number of private hospitals (where the bulk of procedures have been 
performed). Potentially, all patients in SA with PD, severe tremor 
and dystonia who meet appropriate criteria for undergoing DBS 
should be eligible for the procedure. However, restrictions due to 
cost, including the cost of battery replacement, as well as limitations 
arising from the need for trained experts in the field, impact on the 
potential sites where DBS may be carried out.
At the meeting, the public and patients with dystonia and PD 
were represented through the Parkinson’s and Related Movement 
Disorders Association of South Africa. All the known role players 
who were involved with DBS at the time were invited. The follow­
ing, including neurologists, neurosurgeons, neurophysiologists and 
neuro psychologists, and the director of the Parkinson’s and Related 
Movement Disorders Association of South Africa were in atten­
dance: Ms C Bottcher (Life Entabeni Hospital), Dr  D G Anderson 
(University of the Witwaters rand Donald Gordon Hospital), 
Prof. N Cassimjee (University of Pretoria), Prof. J Carr (Stellenbosch 
University, by correspondence), Dr D  Giampaolo (Netcare Rose­
bank Hospital), Prof.  M Lucas (University of the Witwatersrand), 
Dr  R  Melvill (Mediclinic Constantiaberg and University of Cape 
Town), Ms I Nepal (Milpark Hospital), Dr P Slabbert (Netcare 
Rosebank Hospital and University of Pretoria), Dr F Snyckers 
(Milpark Hospital), Dr J Smuts (Life Wilgers Hospital and University 
of Pretoria), Dr J  Vaidyanathan (Medtronic Scientific Representa­
tive), Dr R van Coller (Life Wilgers Hospital and University of 
Pretoria), Ms K  Willemse (Parkinson’s and Related Movement 
Disorders Association of South Africa), Dr C Wolpe (Hillcrest Private 
Hospital) and Dr M Zorio (Milpark Hospital).
At the meeting, it was decided to summarise the current DBS 
literature and provide a practical guideline of best care for DBS in 
patients with PD for general practitioners, neurosurgeons, neurolo­
gists, neurophysiologists, anaesthetists and healthcare funders. 
The guideline was written and edited by Dr Anderson, Dr  Van 
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Coller and Prof. Carr, representing the private and state sectors. The 
completed text was reviewed by Prof. J Volkmann (Department of 
Neurology, Würzburg, Germany), an international authority on DBS. 
The Parkinson’s and Related Movement Disorders Association of 
South Africa, the Neurological Association of South Africa and the 
South African Neurosurgical Association reviewed and endorsed the 
guideline. Annual review of the guideline will be carried out by the 
Movement Disorders Interest Group of South Africa.
Role of sponsor. The guideline has been the voluntary effort 
of Dr  Anderson, Dr Van Coller and Prof. Carr. The meeting was 
sponsored by Medtronic.
3. Cost-effectiveness
Treating PD is complex and expensive, reflecting the complexities 
of the disease and the many complications of therapy. It must be 
noted that DBS with best medical treatment (BMT) is superior to 
BMT alone, and depending on the study, the cost of the DBS device 
is recouped in medication savings alone in 3 ­ 5 years in the case of 
subthalamic nucleus (STN) DBS.[4] Three studies were published in 
2016 addressing the issue of cost­effectiveness of DBS for PD. These 
included a systematic review of the literature on economic studies 
of the use of DBS in patients with PD, including cost studies or 
economic evaluations expressed as cost per improvement in quality 
of life.[5] Nine studies were identified, and the quality­adjusted life 
year (QALY) gain was higher for DBS than for BMT after 2 years. 
A recent study on cost­effectiveness in the USA[6] found DBS to 
be cost­effective. DBS therapy resulted in a discounted QALY gain 
of 1.69 more than BMT (3.19 v. 1.50 QALYs). The corresponding 
10­year costs for DBS and BMT were USD130 510 and USD91 026, 
respectively, leading to an incremental cost­effectiveness ratio of 
USD23 404. DBS was associated with cost increases of ~USD40 000 
over 10  years. However, the cost­effectiveness profile (ratio of 
incremental costs to gained QALYs) was favourable. The authors 
concluded that ‘DBS yields substantial improvements in health­
related quality of life at a value profile that compares favorably to 
other well­accepted therapies.’[6] A study specifically addressing cost­
effectiveness in the early motor complications group found that STN 
DBS was cost­effective in patients aged <61 years compared with 
BMT.[7] The incremental cost­utility ratio for STN DBS compared 
with BMT was EUR22 700 per QALY gained. Overall, DBS reduces 
pharmacological treatment costs and is likely to reduce the direct, 
indirect and social costs of PD in the long term.
4. Evidence for DBS 
The authors reviewed the available evidence for DBS with respect 
to benefit and harm by performing a MEDLINE search using the 
terms ‘deep brain stimulation’ and ‘Parkinson’, selecting the following 
article types: clinical trial, randomised controlled trial and review. In 
addition, material from personal sources and relevant textbooks was 
consulted.
DBS was first used for PD in 1990,[8] and was recognised as a way 
to improve tremor, rigidity and bradykinesia, allowing for a reduction 
in levodopa use.[9] Subsequently, DBS was believed to improve ‘off ’­
time disability, reduce dyskinesia, improve quality of life and lead to 
reduction of the levodopa dose[10] (Table 1). However, it was only in 
2009 that a randomised controlled trial found DBS to be superior to 
BMT in improving ‘on’ time, reducing dyskinesias and improving 
quality­of­life scores.[11] A year later, in a trial of DBS and BMT v. 
BMT alone for advanced PD (PD SURG), it was found that DBS 
and BMT were superior to BMT alone when assessing self­reported 
quality­of­life scores at 1 year[12] (Table 1). Although DBS is accepted 
as an alternative treatment option in patients with advanced PD, the 
EARLYSTIM study showed a substantial benefit in younger patients 
(mean age 52 years) with shorter­duration PD when comparing 
DBS with BMT, and found significant improvement in the primary 
outcome of quality of life[13] (Table 1).
The long­term benefit of DBS has now been shown in 5­ and 
10­year follow­up studies.[10] DBS is still effective in managing 
motor symptoms 10 years after implantation. The usefulness of 
DBS in managing axial features of advanced PD seems to be less 
Table 1. Assessment of evidence for effectiveness of DBS in PD by the PICO approach*
Reference Population Intervention Outcome
Deuschl et al.[10] 156 patients with advanced PD 
and severe motor symptoms
DBS v. BMT PDQ­39 Summary Index (50 of 78 pairs; p=0.02) improved 
9.5 points
UPDRS­III (55 of 78; p<0.001) improved 19.6 points
Williams et al.[12] 366 patients with PD not 
adequately controlled by 
medical therapy
DBS/pallidotomy v. BMT PDQ­39 Summary Index compared with baseline: 
difference of –4.7 points in favour of surgical group 
(p=0.001)
UPDRS­III motor ‘off ’ (–16.8) (p<0.0001)
43 SAEs were surgically related
Weaver et al.[11] PD patients with persistent 
disabling symptoms
121 patients randomised 
equally to pallidotomy or 
DBS v. 134 on BMT
DBS group had 4.6 hours daily improvement in ‘on’ time 
(no change in BMT group)
Significant improvements in the summary measure of 
quality of life and in 7 of 8 PD quality­of­life scores 
(p<0.001)
Largely in first 3 months, significantly greater SAEs for 
surgical group for falls, gait, depression and dystonia
Schuepbach et al.[13] 251 PD patients with disabling 
motor complications present 
for 3 years at most
DBS v. BMT PDQ­39 Summary Index improved from baseline to 24 
months by 26% in DBS group; worsened by 1% in the 
medical therapy group
26 SAEs were surgically related, all but one resolved 
completely
DBS = deep brain stimulation; PD = Parkinson’s disease; PICO = population, intervention, comparison and outcome; BMT = best medical therapy; PDQ­39 = 39­Item Parkinson's Disease 
Questionnaire; UPDRS = Unified Parkinson’s Disease Rating Scale; SAEs = serious adverse events.
*In all trials, the comparison was with BMT.
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robust. A neuroprotective effect from DBS could not be demon­
strated.[14]
DBS surgery is relatively safe, the commonest complications 
being infection, haemorrhage and transient post­surgical confusion. 
The reported complication rate varies widely. In a study of 526 
consecutive patients with DBS implantation, haemorrhage occurred 
in 8.4% of all cases.[15] Bleeds occurred at the entry point or 
subcortically, but rarely in the target, and more often in hypertensive 
patients. Asymptomatic haemorrhage occurred in 3.4% of this series 
of patients, and symptoms were transient in 4.4% of patients and 
permanent in only 0.6%.[15] Approximately 10% of patients were 
reported to have transient postoperative confusion. This has been 
attributed to intracranial contusion, long surgery duration and 
dopamine withdrawal.[16]
5. Target site
Three anatomical basal ganglia targets are suitable for stimulation 
in PD. The target adopted initially was the ventral intermediate 
(VIM) thalamus, which showed a degree of efficacy that was similar 
to thalamotomy for PD­related tremor, but less so for other motor 
features.[17] Altering the target to the GPi resulted in improvement in 
all the major motor features of PD and a reduction in dyskinesia. The 
GPi was then replaced by the STN based on lesion studies in primates 
showing possibly greater efficacy.[18]
A debate has persisted for some time about which site is preferable, 
the STN or the GPi. Randomised controlled trials indicate that 
compared with bilateral GPi DBS, bilateral STN DBS is equally 
effective in treating PD motor symptoms.[19,20] The advantages 
of targeting the STN include good clinical effect on tremor and 
bradykinesia, improvement in dyskinesia and motor fluctuations, 
and the potential to reduce medications.[21] The GPi continues to be 
a potential target, since there remain concerns that STN stimulation 
has a potentially greater effect on cognition and may exacerbate 
neuropsychiatric conditions, and programming and follow­up are 
typically more straightforward for GPi stimulation.[22]
The recommended target in PD is currently the STN. In special 
circumstances, thalamic targets and the GPi may be considered, e.g. 
in elderly patients with dominant PD tremor and little progression 
of akinetic­rigid symptoms (VIM), or frail patients with prominent 
dyskinesia, who might not tolerate the complex and lengthy 
postoperative adjustment of medication and stimulation required in 
STN­DBS.
6. Referral of patients for DBS
The decision when to refer for DBS is not based on level 1 evidence 
and is currently the subject of ongoing debate and investigation. Most 
specialists agree that the optimal time to refer is when patients have 
medication­refractory motor fluctuations, or dyskinesias or tremor 
that are resistant to treatment.
It is important to emphasise that delaying referral may cause harm, 
since it is accepted that the best DBS outcomes are seen in patients 
who are younger, responsive to dopamine and do not have significant 
gait problems. PD patients should be considered for DBS if:
• PD diagnosis is established
• Age at time of surgery is (ideally) <75 years
• Troublesome motor fluctuations or resistant tremor are present
• Dopamine responsiveness is present
• Cognition is normal or minimally impaired
• Gait is impaired, but shows dopamine responsiveness.
Most units will require patients to be known to have PD for >5 years 
in order to exclude patients with atypical parkinsonism. Patients with 
atypical parkinsonism respond poorly to DBS even when there was 
previously documented response to levodopa.
Although age has not been found to be a specific prognostic 
indicator in DBS for PD, increasing age is associated with a number 
of factors that should be considered: medical comorbidity, decreased 
cognitive ability, levodopa resistance and increased surgical risk. 
The recommendation is that patients aged >75 years should only be 
considered in special circumstances.
Accumulating long­term evidence in DBS treatment of PD 
shows poor response of gait and postural instability to stimulation 
treatment. Some aspects of gait and posture may improve initially 
after DBS surgery owing to lengthening of stride and improvement 
of initiation of gait, but rhythmicity and cadence do not seem to 
improve. The gait features that do improve are usually responsive to 
levodopa, and these can be used to predict improvement following 
surgery. Of note, in some patients, gait may even deteriorate after 
surgery.[23] In the long term, patients with advanced PD may have 
progressive issues with gait, freezing of gait, and balance and 
posture, and these features are not effectively addressed by STN 
DBS.[24] DBS should only be considered in patients with gait and 
balance impairment where there is proven levodopa response in 
these domains prior to surgery. Patients should be informed of 
the possible deleterious effect on gait and balance after surgery, 
and similarly should be made aware that gait and balance will not 
respond well to DBS in many cases.
Alternative targets for patients with gait­predominant PD are being 
explored, but no alternative target has been shown to be effective.[23]
7. Patient selection/assessment
The patient selection process consists of assessing the patient 
for suitability for surgery and dopamine responsiveness, and a 
neurocognitive evaluation (sometimes with psychiatric assessment).
7.1 The DBS team
More than 30% of DBS surgery failures can be attributed to inappro­
priate patient selection.[25] Each patient needs to be selected according 
to their individual risk­benefit profile at an expert centre, by a 
multidisciplinary team consisting of an experienced neurologist, 
neurosurgeon and neuropsychologist. This also allows for the patient’s 
expectations to be managed realistically. An expert centre should be 
able to produce an audit of results. Other members of the team, 
but not necessarily seen by every patient, are a neurophysiologist, 
psychiatrist, anaesthetist and neuroradiologist, and ideally a nurse 
with experience in movement disorders.[26]
7.2 Dopamine challenge test
The degree of responsiveness to levodopa is considered to be 
the best predictor for DBS outcomes.[15] The dopamine challenge 
test is performed after a period of dopamine withdrawal (at least 
12 hours) with the patient in the worst ‘off ’ state. Special attention 
must be paid to dopamine agonist withdrawal, since these drugs 
have relatively long half­lives that may affect the assessment of the 
response to the dopamine challenge test. A Unified Parkinson’s 
Disease Rating Scale (UPDRS) III is scored in this state. The 
patient is then given levodopa orally. The dose can vary from 100 
to 250 mg. After at least 1 hour, the UPDRS is scored in the best 
‘on’ state. A 30% improvement is generally considered acceptable 
to proceed to surgery.[27] This has been the operational definition 
for many clinical trials. In clinical practice, however, the quality 
of the ‘best on’ is more important. In particular, the degree of 
levodopa­resistant symptoms should be critically evaluated and 
then discussed with the patient.
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7.3 Neuropsychological testing
Cognitive dysfunction is common in PD, and ranges from mild 
cognitive impairment to dementia.[28] As DBS can impact variably 
on post­surgical cognitive functioning, and frequently worsens 
functions that are associated with the frontostriatal areas, cognitive 
status should be known before surgery.[29­32] It is recommended that 
all patients should be assessed before deciding about surgery, and that 
the assessment of cognitive functioning be carried out by a clinical 
psychologist with specialist knowledge of neuropsychology, or a 
neuropsychologist. Recommendations for the assessment of cognitive 
function in PD have been published.[28,33]
In SA, there are few local normal values for standard 
neuropsychological tests. Education level and not speaking English 
as a first language can influence the outcome of these tests by as much 
as two standard deviations. The neuropsychologist should therefore 
use both quantitative and qualitative approaches where appropriate. 
The underlying mood of the patient, other medical conditions, and 
whether the patient is in the treatment ‘on’ or ‘off ’ state can all affect 
the test outcome.[33]
The presence of significant cognitive impairment in a PD patient 
is an exclusion factor for DBS surgery, particularly if a patient’s 
test profile on a comprehensive battery of neuropsychological tests 
indicates impairment of one or more measures of executive function. 
The presence of mesiotemporal memory impairment (poor encoding 
rather than impaired recall) should alert the neuropsychologist to 
cognitive impairment of a different type to that usually observed 
in executive dysfunction, and suggest further caution regarding a 
decision to proceed to surgery. Individuals with PD who score in the 
borderline range are more susceptible to subtle decline in cognitive 
functioning after surgery,[34] and caution is advised.
8. Surgery
DBS can be done awake with radiological (magnetic resonance 
imaging (MRI)/computed tomography (CT)), electrophysiological 
and clinical guidance or asleep with MRI­based guidance and 
verification of the anatomical target. Both forms of surgery are 
acceptable and have proven outcomes, and units should use the 
method with which they are most familiar.
Awake surgery is performed in two phases. The first phase 
is the stereotactic implantation of the stimulating electrodes in 
the STN. This is usually performed in the awake state to allow 
for electrophysiological recording and stimulation to assess for 
benefits and side­effects. A stereotactic system that maps image 
space to physical space is used to deliver the stimulating electrodes 
to the STN. The trajectory of the electrode is set to avoid critical 
structures of the brain, including blood vessels, sulci and ventricles. 
Microelectrode recording (MER) from individual neurons is typically 
used to identify the neuronal firing patterns during surgery to confirm 
correct positioning. The second phase is the internalisation of the 
neurostimulator, performed under general anaesthesia. This involves 
connecting the stimulating electrodes to the neurostimulator. Both 
phases can be done in one session.
In MRI­guided and verified surgery, the patient receives full 
anaesthesia throughout the surgery, and planning and verification 
of lead placement is done by MRI with the stereotactic frame 
on.[35] In this case, there is no requirement for intraoperative 
neurophysiological recordings, resulting in possible benefits in terms 
of surgical adverse effects and theatre time.
Pre­ and post­surgical imaging form an essential part of both 
surgical techniques and are discussed in section 10. Both techniques 
(awake and asleep) have similar outcomes with regard to motor 
function and reduction in dyskinesia.[11,35]
9. Neurophysiology (MER and 
macroelectrode stimulation (MES))
Despite advances in imaging, most units around the world rely 
on electrophysiological and clinical localisation to confirm and 
refine the radiological target.[36] The first phase in intraoperative 
electrophysiology is to perform MER. Up to five test electrodes can 
be advanced simultaneously in micrometric steps to the radiological 
target and beyond. The different anatomical targets in the basal 
ganglia each have a unique electrophysiological footprint that defines 
the boundaries of the target.
The second phase in the determination of the physiological 
boundaries of the target involves electrical stimulation with a macro­
test electrode. MES is done to assess clinical effect and stimulation­
related adverse effects before permanent placement of the DBS lead. 
Someone trained in movement disorders, such as a neurologist, 
neurosurgeon or specifically trained PD nurse, should perform the 
assessments.
Stimulation is performed using a constant­current stimulator 
on the MER system with standard settings. Monopolar stimulation 
at predefined intervals is done in incrementing current strengths 
(generally 1 ­ 5 mA) to assess the area delineated by MER and 
imaging.
Clinical benefits of acute intraoperative MES are monitored with 
contralateral wrist rigidity, tremor and bradykinesia.[37] When there is 
little or no clinical effect at amplitude settings of up to 3 mÅ, it should 
be considered that the position in the STN is not optimal.
Side­effects secondary to stimulation include contralateral 
muscle contractions and/or eye deviation. Side­effects are classified 
as transient or persistent and mild, moderate or severe. Only 
stimulation­induced side­effects after the supramaximal threshold 
are considered acceptable to choose a trajectory for implanting 
the permanent DBS lead. A combination of acceptable clinical 
effects on tremor, rigidity and bradykinesia without the induction 
of persisting adverse effects is required to assure optimal lead 
placement.[36]
10. Imaging
10.1 Imaging before surgery
Imaging the brain is essential for the preoperative target planning 
in DBS. Acceptable imaging modalities for targeting include MRI, 
CT and ventriculography. T2­weighted imaging or susceptibility­
weighted imaging (SWI) is generally considered useful to delineate 
the target and to indicate which neighbouring structures to avoid, 
and at least 1.5 Tesla field strength is recommended. Whole­brain 
T1­weighted imaging with contrast is used for planning and ensuring 
a safe trajectory to the target and verifying the entire course from 
cortical entry to target.[26]
10.2 Imaging after surgery
Post­surgical imaging is somewhat controversial. The majority 
of units agree that some form of imaging is necessary to ensure 
that the leads are in position. This then acts a reference point 
in the case of subsequent limited benefit, adverse effects or lead 
displacement. In a consensus document, a CT scan was judged 
to be adequate, but MRI was generally seen as superior to CT.[26] 
However, there is concern in performing MRI following DBS, as it 
can result in heating of the leads, magnetic field interactions and 
movement of the components, induced currents, and functional 
disruption of the DBS components. [38] Carefully following 
manufacturer guidelines permits the use of conditionally safe 
MRI scans to audit the lead location. Larson et al.[39] demonstrated 
safety in >1 000 MRI examinations. The DBS Study Group of 
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the National Parkinson Foundation has scanned >3 304 patients 
without any complications.[40]
Our recommendation is that post­surgical imaging with at least CT 
imaging with a presurgical MRI merge is necessary, although post­
surgical MRI is preferred.
11. Programming
Programming of the device is as important as accurate electrode 
placement in ensuring successful treatment. To ensure the full 
benefit of this specialised treatment, programming should be done 
by a trained specialist. Managing programming cannot be done in 
isolation from medication adjustments and other treatments, so a 
neurologist with training or experience in DBS should preferably be 
in charge of programming.
The programming process consists of the initial programming, 
follow­up sessions in the weeks after surgery, and long­term follow­
up once symptom control and medication adjustment are stable.
The standard DBS electrode consists of four 1.5 mm cylindrical 
contacts each spaced 0.5 mm from one other. Various programming 
options can be used to maximise the clinical effect. These include the 
use of different contacts in mono­ or bipolar mode and adjusting the 
voltage/current, pulse width and frequency of stimulation.[41]
The initial programming is patient specific and depends on the 
microlesion effect (positive surgical effect that can last several 
weeks), the side­effects of stimulation, the patient’s stamina and 
whether bilateral stimulation is required. Initial programming 
should preferably be done when the patient is in the off­medication 
phase.[41]
Initial follow­up programming sessions address habituation of the 
stimulation effect and the complete resolution of the microlesioning 
effect after surgery. Increases in stimulation are generally required, 
although in some patients other parameter changes may prove 
necessary. Checking of impedance (resistance of the electrode and 
electrode­tissue barrier to electrical stimulation) and battery life is 
advised. Careful documentation of each programming session is very 
important for future reference.
Long­term follow­up includes device and battery checks, and 
adjustment of stimulation and medication to allow for symptom 
control with progression of disease. Intervals are patient specific.
12. Managing pharmacological 
treatment
The aim of DBS is not to withdraw medication completely, but 
to improve the patient’s quality of life. Medication reduction and 
post­surgical management need to be done by an experienced 
neurologist with an understanding of DBS and medication 
interactions. Special care in terms of the dopamine agonist 
withdrawal syndrome is required.[42] When adjusting DBS 
programming, medication adjustments must be made in parallel. 
Stimulation should improve parkinsonian signs; dopaminergic 
drugs can be slowly reduced if this is seen. Dyskinesias are often 
increased with STN stimulation for a short time after stimulation 
is initiated, another reason for medication reduction.[15] Sudden 
stopping of dopaminergic therapy can result in withdrawal 
syndromes.[43] These include motor and delayed non­motor 
symptoms such as apathy and depression. STN stimulation 
may result in euphoria or even hypomania with a dopamine 
dysregulation syndrome, which requires dopamine reduction. 
DBS patients must be assessed regularly to optimise both motor 
and behavioural states, by titrating stimulation with levodopa 
to avoid akinesia or dyskinesia, and by careful adjustment of 
medication to avoid apathy or impulse control disorders.[44]
13. Recommendations
Based on the outcome of the initial workshop, review of the literature, 
consultation with patient groups and input from an external 
expert consultant, the following are the key points concerning the 
management of DBS in PD:
• DBS is a safe and effective treatment for carefully selected patients 
with PD (section 4). 
• Patients should be carefully selected for symptoms that are known 
to respond to DBS (section 6).
• Patients need to undergo dopamine challenge testing to assess the 
degree of response to dopamine (section 7.2).
• Patients should undergo neuropsychological testing, and the pres­
ence of significant cognitive impairment is usually a contraindica­
tion to DBS (section 7.3).
• Currently, several radiological approaches to selecting an 
appropriate target may be used, and both intraoperative physio­
logical recordings and MRI­verified approaches are valid methods 
of performing DBS (sections 8 and 9).
• Careful follow­up and programming of the DBS system is mandatory, 
and a major reason for DBS failure is inadequate programming and 
management of medication (sections 11 and 12).
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